S&P 500 gains to extend record run, set for positive week
In a recent transaction, Ashim Gupta, the Chief Operating Officer and Chief Financial Officer of UiPath, Inc. (NYSE:PATH), sold a significant portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Gupta sold a total of 99,300 shares of UiPath’s Class A Common Stock on May 1, 2025. The sales were executed under a pre-arranged 10b5-1 trading plan, with prices ranging from $12.00 to $12.0500 per share. The company, currently trading at $11.98, shows strong financial health with an impressive 83% gross profit margin and more cash than debt on its balance sheet, according to InvestingPro data.
The total value of the shares sold amounted to approximately $1.19 million. Following these transactions, Gupta retains ownership of 987,322 shares directly. Additionally, a small portion of the shares was sold indirectly through a trust, leaving zero shares in that account post-transaction.
These sales are part of routine financial management and are conducted under a pre-established trading plan to ensure compliance with insider trading regulations.
In other recent news, UiPath has introduced a new AI-based medical record summarization tool aimed at reducing administrative time in the healthcare sector. This tool, developed in collaboration with clinical professionals and powered by Google (NASDAQ:GOOGL) Cloud Vertex (NASDAQ:VRTX) AI, is expected to significantly cut down the time required for processing medical records. Meanwhile, analysts have been adjusting their outlook on UiPath following its recent financial performance. BMO Capital Markets lowered its price target for UiPath to $11.50 from $16.00, citing missed revenue and Annual Recurring Revenue (ARR) estimates, along with concerns over the company’s growth prospects. Similarly, TD Cowen reduced its price target to $12.00 from $16.00, maintaining a Hold rating due to uncertainties in the company’s fiscal year 2026 outlook and broader market conditions. RBC Capital Markets also adjusted its price target to $13.00 from $16.00, expressing disappointment over UiPath’s Net New Annual Recurring Revenue and maintaining a Sector Perform rating. Needham, on the other hand, reaffirmed its Hold rating, noting UiPath’s strategic vision for agentic orchestration and upcoming product launches. Investors are closely monitoring UiPath’s developments in AI and automation technology as the company navigates a competitive landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.